Literature DB >> 15052278

Intact cross-talk between insulin secretion and insulin action after postgastroplasty recovery of ideal body weight in severely obese patients.

M R Letiexhe1, C Desaive, P J Lefèbvre, A J Scheen.   

Abstract

Most reports investigating the hormonal and metabolic effects of bariatric surgery studied obese subjects after partial weight loss only. Nevertheless, all studies showed significant improvements of insulin secretion, action, clearance and inhibition of its own secretion, although the parallel kinetics of all these changes remained questionable. Using the intravenous glucose tolerance test, we demonstrated a full normalization of insulin secretion, action on glucose metabolism and clearance in eight obese women who recovered and maintained ideal body weight following gastroplasty. Reciprocal changes were observed between postglucose acute insulin secretion and insulin-mediated glucose disposal so that the so-called disposition index (product of these two variables) remained unchanged after vs before gastroplasty in those individuals with normal glucose tolerance. These favourable results should encourage obtaining a drastic and sustained weight loss in patients with severe obesity at risk of developing type II diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15052278     DOI: 10.1038/sj.ijo.0802632

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  2 in total

1.  Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function.

Authors:  A Mari; M Manco; C Guidone; G Nanni; M Castagneto; G Mingrone; E Ferrannini
Journal:  Diabetologia       Date:  2006-07-04       Impact factor: 10.122

2.  Improvement in ß-cell function in patients with normal and hyperglycemia following Roux-en-Y gastric bypass surgery.

Authors:  Edward Lin; Zhe Liang; Jennifer Frediani; Scott S Davis; John F Sweeney; Thomas R Ziegler; Lawrence S Phillips; Nana Gletsu-Miller
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-08-17       Impact factor: 4.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.